<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        9-584-09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2009
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NEOCIPRO 500MG F.C. TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CIPROFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        24.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NEOPHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NEOPHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NEOPHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tablets<br />Broad spectrum antimicrobial agent<br />Composition (Active ingredient only) :<br />Each film-coated tablet contains Ciprofloxacin Hydrochloride BP equivalent to<br />Ciprofloxacin 250mg or 500mg.<br />Introduction:<br />Neocipro contains ciprofloxacin, a broad spectrum antibacterial agent effective<br />against a wide range of microorganisms.<br />Neocipro is rapidly and well absorbed from the gastrointestinal tract after oral<br />administration. The drug undergoes metabolism into four metabolites whose<br />antimicrobial activity is less than unchanged ciprofloxacin.<br />In subjects with normal renal function, the elimination half-life is approximately<br />4 hours and about 40-50% of an orally administered drug is excreted<br />unchanged in the urine.<br />Mode of action and antimicrobial spectrum:<br />Ciprofloxacin has a bactericidal action and this is a result of inhibition of the<br />enzyme topoisomerase II and topoisomerase IV which are required for bacterial<br />replication, transcription, repair and recombination.<br />Ciprofloxacin has antibacterial activity against a wide range of Gram-positive<br />and Gram-negative microorganisms which includes the following:<br />Aerobic Gram-positive organisms including:<br />Enterococcus faecalis (Many strains are only moderately susceptible)<br />Staphylococcus aureus (methicillin susceptible strains only)<br />Staphylococcus saprophyticus<br />Streptococcus pneumoniae (penicillin susceptible strains only)</p><p>Aerobic Gram-negative organisms including</p><p>Campylobacter jejuni<br />Citrobacter diversus<br />Citrobacter freundii<br />Enterobacter cloacae<br />Escherichia coli<br />Haemophilus influenzae<br />Haemophilus parainfluenzae<br />Klebsiella pneumoniae<br />Moraxella catarrhalis<br />Morganella morganii<br />Neisseria gonorrhoeae<br />Proteus mirabilis<br />Providencia rettgeri<br />Providencia stuartii<br />Pseudomonas aeruginosa<br />Salmonella typhi<br />Serratia marscescens<br />Shigella boydii<br />Shigella dysentriae<br />Shigella flexneri<br />Shigella sonnei</p><p>Indications:<br />Ciprofloxacin is indicated in the management of following infections caused<br />by susceptible microorganisms.<br />Urinary tract infections<br />Acute uncomplicated cystitis in females<br />Lower respiratory tract infections<br />Acute sinusitis<br />Bone and joint infections<br />Infectious diarrhoea<br />Typhoid fever<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Contraindications:<br />Ciprofloxacin is contraindicated in persons with a history of hypersensitivity<br />to ciprofloxacin or any member of the quinolone class of antimicrobial<br />agents.<br />Warnings:<br />The safety and use of ciprofloxacin in pediatric patients and adolescents<br />(less than 18 years of age), pregnant women and lactating women have not<br />been established.<br />Precautions:<br />Crystals of ciprofloxacin have been observed rarely in the urine of human<br />subjects. In patients receiving ciprofloxacin, alkalinity of urine should be<br />avoided and they should be well hydrated to prevent the formation of highly<br />concentrated urine.<br />Dosage alteration of ciprofloxacin is necessary in the case of renally<br />impaired patients. (Please refer to dosage)<br />Patients on ciprofloxacin should avoid excessive sunlight as moderate to<br />severe phototoxicity manifestation as an exaggerated sunburn reaction has<br />been observed in patients who are exposed to direct sunlight while receiving<br />some members of the quinolone class of drugs.<br />Periodic monitoring of renal, hepatic and hematopoietic function is advisable<br />during prolonged therapy.<br />Ciprofloxacin should be used with caution in epileptics and in patients with a<br />history of CNS disorders. Patients with defects in glucose-6-phosphate<br />dehydrogenase activity are prone to haemolytic reactions with quinolones,<br />hence ciprofloxacin should be administered with caution in these patients.<br />Tendon inflammation and rupture may occur with quinolone antibiotics<br />particularly in elderly patients and in those patients who are on concurrent<br />corticosteroid therapy.<br />There is a risk of pseudomembranous colitis with ciprofloxacin. In such<br />cases, ciprofloxacin should be discontinued and an appropriate treatment<br />given.<br />Ciprofloxacin should be used with caution in patients with myasthenia gravis.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dosage:<br />Neocipro dosage is based on the type and severity of infection as described<br />in the dosage table :<br />*Generally ciprofloxacin should be continued for at least 2days after the signs<br />and symptoms of infection have disappeared.<br />In patients with renal impairment, dosage modifications are necessary. The<br />recommended starting and maintenance doses for patients with impaired renal<br />function are presented in the table below.<br />Side Effects:<br />The most frequently reported side effects include nausea, diarrhoea, vomiting,<br />abdominal pain/discomfort, headache, restlessness and rash.<br />Other less commonly observed side effects include foot pain, palpitation,<br />dizziness, light-headedness, insomnia, painful oral mucosa, lymphadenopathy,<br />arthralgia, joint stiffness, interstitial nephritis, dyspnea, epistaxis, pruritus,<br />urticaria, photosensitivity, flushing, fever, chills, angioedema, blurred vision and<br />decreased visual acuity.<br />Quinolones, including ciprofloxacin, may cause central nervous system events<br />including nervousness, agitation, insomnia, anxiety, nightmare or paranoia. It<br />may exacerbate symptoms of myasthenia gravis.<br />Overdosage:<br />In the event of overdosage, the stomach should be emptied by inducing emesis<br />or by gastric lavage. Adequate hydration must be maintained.<br />Use in Pregnancy and Lactation:<br />The use of ciprofloxacin in pregnancy and lactation is not recommended.<br />Drug interactions:<br />Concomitant administration of ciprofloxacin along with theophylline may lead to<br />elevated serum concentrations of theophylline and prolongation of its<br />elimination half-life leading to increased risk of theophylline-related side effects.<br />Administration of ciprofloxacin and caffeine may lead to reduced clearance of<br />caffeine and a prolongation of its half-life.<br />Concurrent administration of ciprofloxacin and multivalent cation-containing<br />products such as aluminum and magnesium antacids, sucralfate, products<br />containing calcium, iron or zinc may decrease the absorption of ciprofloxacin<br />resulting in lower serum and urine concentrations.<br />The concomitant administration of phenytoin and ciprofloxacin has resulted in<br />altered levels of phenytoin.<br />Quinolones have shown to increase the effects of the oral anticoagulant<br />warfarin or its derivatives, hence constant monitoring of prothrombin time or<br />suitable coagulation test should be made.<br />The administration of ciprofloxacin along with glibenclamide, rarely, has<br />resulted in severe hypoglycaemia.<br />Concomitant administration of cyclosporine can cause transient elevation in<br />serum creatinine.<br />Presentation :<br />Packs of 10 or 100tablets.<br />Storage :<br />Store in a dry place below 25&deg;C.<br />Campylobacter jejuni<br />Citrobacter diversus<br />Citrobacter freundii<br />Enterobacter cloacae<br />Escherichia coli<br />Haemophilus influenzae<br />Haemophilus parainfluenzae<br />Klebsiella pneumoniae<br />Moraxella catarrhalis<br />Morganella morganii<br />Neisseria gonorrhoeae<br />Proteus mirabilis<br />Providencia rettgeri<br />Providencia stuartii<br />Pseudomonas aeruginosa<br />Salmonella typhi<br />Serratia marscescens<br />Shigella boydii<br />Shigella dysentriae<br />Shigella flexneri<br />Shigella sonnei<br />Infection Severity Unit dose Frequency Duration*<br />Urinary<br />tract<br />Acute<br />uncomplicated 250mg q 12h 3days<br />Mild /<br />moderate 250mg q 12h 7 to 14<br />days<br />Severe /<br />complicated 500mg q 12h 7 to 14<br />days<br />Lower<br />respiratory<br />tract<br />Mild /<br />moderate 500mg q 12h 7 to 14<br />days<br />Acute<br />sinusitis<br />Mild /<br />moderate 500mg q 12h 10days<br />Skin<br />and skin<br />structure<br />Mild/ moderate 500mg q 12h 7 to 14</p><p>Joint<br />Mild/ moderate 500mg q 12h &ge; 4 to 6<br />weeks<br />Infectious<br />diarrhoea<br />Mild/<br />moderate/<br />severe<br />500mg q 12h 5d atoy s7<br />Typhoid<br />fever<br />Mild/ moderate 500mg q 12h 10days<br />Uncomplicated 250mg Single<br />dose<br />Single<br />dose<br />Infection Severity Unit dose Frequency Duration*<br />Urethral<br />and cervical<br />gonococcal<br />infections</p><p>Generally ciprofloxacin should be continued for at least 2days after the signs<br />and symptoms of infection have disappeared.<br />In patients with renal impairment, dosage modifications are necessary. The<br />recommended starting and maintenance doses for patients with impaired renal<br />function are presented in the table below&nbsp;</p><p>Creatinine Clearance (ml/min) Dose<br />&gt;50 Usual dosage<br />30-50 250-500mg q 12h<br />5-29 250-500mg q 18h<br />Patients on hemodialysis or<br />peritoneal dialysis<br />250-500mg q 24h (after<br />dialysis)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Side Effects:<br />The most frequently reported side effects include nausea, diarrhoea, vomiting,<br />abdominal pain/discomfort, headache, restlessness and rash.<br />Other less commonly observed side effects include foot pain, palpitation,<br />dizziness, light-headedness, insomnia, painful oral mucosa, lymphadenopathy,<br />arthralgia, joint stiffness, interstitial nephritis, dyspnea, epistaxis, pruritus,<br />urticaria, photosensitivity, flushing, fever, chills, angioedema, blurred vision and<br />decreased visual acuity.<br />Quinolones, including ciprofloxacin, may cause central nervous system events<br />including nervousness, agitation, insomnia, anxiety, nightmare or paranoia. It<br />may exacerbate symptoms of myasthenia gravis.</p><p>Overdosage:<br />In the event of overdosage, the stomach should be emptied by inducing emesis<br />or by gastric lavage. Adequate hydration must be maintained.<br />Use in Pregnancy and Lactation:<br />The use of ciprofloxacin in pregnancy and lactation is not recommended.<br />Drug interactions:<br />Concomitant administration of ciprofloxacin along with theophylline may lead to<br />elevated serum concentrations of theophylline and prolongation of its<br />elimination half-life leading to increased risk of theophylline-related side effects.<br />Administration of ciprofloxacin and caffeine may lead to reduced clearance of<br />caffeine and a prolongation of its half-life.<br />Concurrent administration of ciprofloxacin and multivalent cation-containing<br />products such as aluminum and magnesium antacids, sucralfate, products<br />containing calcium, iron or zinc may decrease the absorption of ciprofloxacin<br />resulting in lower serum and urine concentrations.<br />The concomitant administration of phenytoin and ciprofloxacin has resulted in<br />altered levels of phenytoin.<br />Quinolones have shown to increase the effects of the oral anticoagulant<br />warfarin or its derivatives, hence constant monitoring of prothrombin time or<br />suitable coagulation test should be made.<br />The administration of ciprofloxacin along with glibenclamide, rarely, has<br />resulted in severe hypoglycaemia.<br />Concomitant administration of cyclosporine can cause transient elevation in<br />serum creatinine.<br />Presentation :<br />Packs of 10 or 100tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store in a dry place below 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                NA
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>NEOPHARMA</p><p>Abu Dhabi, UAE</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                11/2011
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>أقراص<br />مضاد للميكروبات واسع الطيف<br />التركيب (المادة الفعَّالة فقط):<br />كل قرص مغَّلف يحتوي على سيبروفلوكساسين هيدروكلورايد( ف . ب) ما يكافئ<br />٢٥٠ ملجم أو ٥٠٠ ملجم سيبروفلوكساسين.<br />مقدمة:<br />نيوسيبرو يحتوي على سيبروفلوكساسين، مضاد للبكتيريا واسع الطيف، فعَّال ضد مجال واسع من<br />الكائنات الدقيقة.<br />يتم امتصاص نيوسيبرو بسرعة و بشكل جيد من القناة الهضمية بعد تناوله عن طريق الفم . الدواء<br />يخضع لعمليات الأيض معط ً يا أربع منتجات أيضية أقل فعالية من السيبروفلوكساسين .<br />٪ ٥٠- عندالمرضى الذين لديهم وظائف كلى عادية ، مدة نصف العمر لإخراجه حوالي ٤ ساعات، ٤٠<br />تقريباً من الدواء المأخوذ عن طريق الفم يتم إخراجه في البول دون تغيير.<br />ميكانيكية التأثير و مجاله ضد الميكروبات:<br />سيبروفلوكساسين يملك تأثير قاتل للبكتيريا ناتج عن تثبيطه للإنزيمات توبوايزوميريز ٢ و توبوايزوميريز<br />٤ اللازمة لعمليات تكاثر البكتيريا (الانقسام، النسخ، إعادة التجهيز، إعادة الارتباط).<br />التأثير المضاد للبكتيريا لدى السيبروفلوكساسين يشمل العديد من الكائنات الموجبة و السالبة<br />الغرام منها:<br />البكتيريا الهوائية الموجبة الغرام وتشمل:<br />انتيروكوكس فيساليز (عدة فصائل منها حسَّاسة بشكل متوسط)<br />ستافيلوكوكس أورياس (الفصائل الحسَّاسة للميثيسلين فقط)<br />ستافيلوكوكس سابروفيتيكس<br />ستربتوكوكس بنيمونيا ( الفصائل المستجيبة للبنسلين فقط)</strong></p><p><strong>البكتيريا الهوائية السالبة الغرام و تشمل:</strong></p><p><strong>كامبيلو باكتر جيجوني<br />سيتروباكتر دايفيرسس<br />سيتروباكتر فرويندي<br />انتيروباكتر كلوسيه<br />ايشرشيا كولاي<br />هيموفيليس انفلونزا<br />هيموفيليس بارانفلونزا<br />كليبسيلا بنيمونيا<br />موراكسيلا كاتاراليس<br />مورجانيلا مورجاني<br />نيسيريا جونوريا<br />بروتياس ميرابيليس<br />بروفيدنسيا رتجيري<br />بروفيدنسيا ستاورتي<br />سيدوموناس أوروجينوزا<br />سالمونيلا تايفي<br />سيراتيا مارسيسينز<br />شيجيلا بويدي<br />شيجيلا ديسنتري<br />شيجيلا فلكسنيري<br />شيجيلا سوني</strong></p><p><strong>دواعي الاستعمال:<br />يوصى باستعمال نيوسيبرو لعلاج العدوى المتسببة عن البكتيريا المستجيبة له و تشمل:<br />عدوى الجهاز البولي<br />عدوى المثانة الحادة الغير معقدة عند النساء<br />عدوى الجهاز التنفسي السفلي<br />عدوى الجيوب الأنفية الحادة<br />عدوى العظام و المفاصل<br />الإسهال المعدي<br />حمى التيفوئيد</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع الاستعمال:<br />يمنع استعمال سيبروفلوكساسين من قبل المرضى الذين لديهم حساسية مفرطة من<br />السيبروفلوكساسين أو أي من المضادات الحيوية من أفراد مجموعة الكينولون.<br />تحذيرات:<br />سلامة استخدام السيبروفلوكساسين من قبل الصغار، المراهقين (أقل من ١٨ سنة )، الحوامل و<br />المرضعات لم تتأكد بعد.<br />الاحتياطات:<br />لوحظ وجود بلورات سيبروفلوكساسين في حالات نادرة في البول لدى الإنسان. المرضى الذين<br />يستخدمون السيبروفلوكساسين يجب أن يتجنبوا قلوية البول كما يجب أن يتناولوا الكثير من<br />السوائل لمنع تكوين بول مركَّز. من الضروري تعديل الجرعة في حالة المرضى الذين لديهم خلل في<br />وظائف الكلى(ارجع إلى الجرعة من فضلك).<br />المرضى الذين يستخدمون سيبروفلوكساسين يجب أن يتجنبوا ضوء الشمس الشديد نظراً لأنَّه<br />لوحظ حدوث حالات متوسطة إلى شديدة من الحروق الشمسية في المرضى الذين يتعرضون لضوء<br />الشمس المباشر بينما يتناولون بع ً ضا من أفراد الكينولونات.<br />ينصح بعمل فحص دوري لوظائف الكلى، الكبد، الدم خلال العلاج الطويل بالسيبروفلوكساسين.<br />يجب أن يستعمل السيبروفلوكساسين بحذر من قبل المرضى الذين يعانون من مرض الصرع أو أمراض<br />الجهاز العصبي المركزي ،<br />المرضى الذين لديهم نقص في نشاط جلوكوز ٦فوسفات ديهيدروجينيز معرضون لتفاعلات تكسير<br />الدم في حال استخدام الكينولونات، لذلك يجب استخدام السيبروفلوكساسين بحذر لدى هؤلاء<br />المرضى .<br />التهاب الأوتار و تكسرها قد تحدث مع الكينولونات خاصة عند المرضى كبار السن و المرضى الذين<br />يخضعون للعلاج بالكورتيكوستيرويد .<br />هناك احتمالية حدوث التهاب الغشاء القولوني الكاذب في حال استعمال السيبروفلوكساسين . في<br />تلك الحالة يجب الانقطاع عن تناول السيبروفلوكساسين و استعمال العلاج المناسب .<br />يجب استعمال سيبروفلوكساسين بحذر لدى المرضى الذين يعانون من الوهن العضلي الوبيل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><br /><br />NA<br /><br /><br /><br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>الآثار الجانبية الأكثر حدوثًا تشمل الغثيان، الإسهال، القيئ، آلام في البطن، صداع، ارتخاء، طفح جلدي.<br />الآثار الجانبية الأخرى الأقل حدوثاً تشمل ألم القدم، خفقان، دوخة ،دوار الرأس، أرق، ألم في الأغشية<br />اﻟﻤﺨاطية للفم، اعتلال عقدي لمفي، آلام المفاصل ، تصلب المفاصل، التهاب الكلى الخلالي، ضيق النفس،<br />رعاف، حكة، ارتكاريا، حساسية ضوئية، احمرار، حمى، قشعريرة، وذمة وعائية، ضبابية الرؤية، نقص في<br />حدة النظر.<br />الكينولونات بما فيها السيبروفلوكساسين قد تؤثر على الجهاز العصبي المركزي مؤدية إلى عصبية،<br />هياج، أرق، غضب، كابوس ليلاً، ذهان. قد يسبب تفاقم لأعراض الوهن العضلي الوبيل.<br />الجرعة المفرطة:<br />في حال زيادة الجرعة، يجب تفريغ المعدة بالحث على التقيؤ أو بالغسيل المعدي. كذلك يجب المحافظة<br />على نسبة السوائل في الجسم.<br />الاستخدام في الحمل و الرضاعة:<br />لا ينصح باستخدام السيبروفلوكساسين من قبل الحامل و المرضع.<br />التداخلات الدوائية:<br />-تناول السيبروفلوكساسين بالترافق مع الثيوفيللين قد يؤدي إلى ارتفاع تركيز الثيوفيللين في<br />المصل و إطالة فترة نصف العمر لإخراجه مما يؤدي إلى زيادة خطر حدوث الآثار الجانبية من<br />الثيوفيللين.<br />- تناول السيبروفلوكساسين و الكافيين في نفس الوقت قد يؤدي إلى نقص تصفية الكافيين و إطالة<br />فترة نصف عمره.<br />-الاستخدام المترافق للسيبروفلوكساسين مع المواد المحتوية على كاتيونات عديدة التكافؤ مثل<br />مضادات الحموضة المحتوية على الالومنيوم و الماغنيسيوم، سكرالفات ، المواد المحتوية على كالسيوم،<br />حديد، زنك قد تؤدي إلى نقص امتصاص السيبروفلوكساسين مما ينتج عنه انخفاض تركيزه في المصل<br />و البول.<br />- تناول الفينيتوين مع السيبروفلوكساسين يؤدي إلى تغيرات في مستوى الفينيتوين.<br />- لوحظ أن الكينولونات تزيد تأثير مضادات التخثر مثل الوارفارين أو مشتقاته، لهذا يجب عمل<br />اختبارات لوقت البروثرومبين أو التخثر بشكل دوري.<br />- تناول السيبروفلوكساسين بالتزامن مع الجليبنكلامايد نادرًا ما نتج عنه انخفاض شديد في مستوى<br />السكر في الدم.<br />- الاستخدام المتزامن له مع السايكلوسبورين قد يؤدي إلى ارتفاع مؤقت في تركيز الكرياتنين في<br />المصل .<br />العبوات :<br />أقراص : عبوات تحتوي على ١٠ أو ١٠٠ قرص.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>التخزين:<br />يحفظ في مكان جاف في درجة حرارة أقل من ٢٥ ْم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>NA</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>نيوفارما&nbsp;أبوظبي، ا.ع.م</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            11/2011
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Neocipro 500 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 500 mg ciprofloxacin (as hydrochloride).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Neocipro 500 mg film-coated tablets are indicated for the treatment of the following infections (see sections 4.4 and 5.1). Special attention should be paid to available information on resistance to ciprofloxacin before commencing therapy.<br />Consideration should be given to official guidance on the appropriate use of antibacterial agents.<br />Adults<br />&bull; Lower respiratory tract infections due to Gram-negative bacteria<br />- exacerbations of chronic obstructive pulmonary disease<br />- broncho-pulmonary infections in cystic fibrosis or in bronchiectasis<br />- pneumonia<br />&bull; Chronic suppurative otitis media<br />&bull; Acute exacerbation of chronic sinusitis especially if these are caused by Gram-negative bacteria<br />&bull; Urinary tract infections<br />&bull; Genital tract infections<br />- gonococcal uretritis and cervicitis due to susceptible Neisseria gonorrhoeae<br />- epididymo-orchitis including cases due to susceptible Neisseria gonorrhoeae<br />- pelvic inflammatory disease including cases due to susceptible Neisseria gonorrhoeae</p><p>&bull; Infections of the gastro-intestinal tract (e.g. travellers&#39; diarrhoea)<br />&bull; Intra-abdominal infections<br />&bull; Infections of the skin and soft tissue caused by Gram-negative bacteria<br />&bull; Malignant external otitis<br />&bull; Infections of the bones and joints<br />&bull; Prophylaxis of invasive infections due to Neisseria meningitidis<br />&bull; Inhalation anthrax (post-exposure prophylaxis and curative treatment)<br />Ciprofloxacin may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.<br />Children and adolescents<br />&bull; Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa<br />&bull; Complicated urinary tract infections and pyelonephritis<br />&bull; Inhalation anthrax (post-exposure prophylaxis and curative treatment)<br />Ciprofloxacin may also be used to treat severe infections in children and adolescents when this is considered to be necessary.<br />Treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents (see sections 4.4 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The dosage is determined by the indication, the severity and the site of the infection, the susceptibility to ciprofloxacin of the causative organism(s), the renal function of the patient and, in children and adolescents the body weight.<br />The duration of treatment depends on the severity of the illness and on the clinical and bacteriological course.<br />Treatment of infections due to certain bacteria (e.g. Pseudomonas aeruginosa, Acinetobacter or Staphylococci) may require higher ciprofloxacin doses and co-administration with other appropriate antibacterial agents.</p><p>Treatment of some infections (e.g. pelvic inflammatory disease, intra-abdominal infections, infections in neutropenic patients and infections of bones and joints) may require co-administration with other appropriate antibacterial agents depending on the pathogens involved.<br />Adults<br />Indications<br />Daily dose in mg<br />Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin)<br />Infections of the lower respiratory tract<br />500 mg twice daily to 750 mg twice daily<br />7 to 14 days<br />Infections of the upper respiratory tract<br />Acute exacerbation of chronic sinusitis<br />500 mg twice daily to 750 mg twice daily<br />7 to 14 days<br />Chronic suppurative otitis media<br />500 mg twice daily to 750 mg twice daily<br />7 to 14 days<br />Malignant external otitis<br />750 mg twice daily<br />28 days up to 3 months<br />Urinary tract infections (see section 4.4)<br />Uncomplicated cystitis<br />250 mg twice daily to 500 mg twice daily<br />3 days<br />In pre-menopausal women, 500 mg single dose may be used<br />Complicated cystitis, Uncomplicated pyelonephritis<br />500 mg twice daily<br />7 days<br />Complicated pyelonephritis<br />500 mg twice daily to 750 mg twice daily<br />at least 10 days, it can be continued for longer than 21 days in some specific circumstances (such as abscesses)<br />Prostatitis<br />500 mg twice daily to 750 mg twice daily<br />2 to 4 weeks (acute) to 4 to 6 weeks (chronic)<br />Genital tract infections<br />Gonococcal uretritis and cervicitis<br />500 mg as a single dose<br />1 day (single dose)<br />Epididymo-orchitis and pelvic inflammatory diseases<br />500 mg twice daily to 750 mg twice daily<br />at least 14 days</p><p>Infections of the gastro-intestinal tract and intra-abdominal infections<br />Diarrhoea caused by bacterial pathogens including Shigella spp. other than Shigella dysenteriae type 1 and empirical treatment of severe travellers&#39; diarrhoea<br />500 mg twice daily<br />1 day<br />Diarrhoea caused by Shigella dysenteriae type 1 500 mg twice daily<br />5 days<br />Diarrhoea caused by Vibrio cholerae<br />500 mg twice daily<br />3 days<br />Typhoid fever<br />500 mg twice daily<br />7 days<br />Intra-abdominal infections due to Gram-negative bacteria<br />500 mg twice daily to 750 mg twice daily<br />5 to 14 days<br />Infections of the skin and soft tissue<br />500 mg twice daily to 750 mg twice daily<br />7 to 14 days<br />Bone and joint infections<br />500 mg twice daily to 750 mg twice daily<br />max. of 3 months<br />Neutropenic patients with fever suspected to be due to a bacterial infection.<br />Ciprofloxacin should be co-administered with appropriate antibacterial agent(s) in accordance to official guidance.<br />500 mg twice daily to 750 mg twice daily<br />Therapy should be continued over the entire period of neutropenia<br />Prophylaxis of invasive infections due to Neisseria meningitidis<br />500 mg as a single dose<br />1 day (single dose)<br />Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate.<br />500 mg twice daily<br />60 days from the confirmation of Bacillus anthracis exposure</p><p>Indications<br />Daily dose in mg<br />Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin)<br />Cystic fibrosis<br />20 mg/kg body weight twice daily with a maximum of 750 mg per dose.<br />10 to 14 days<br />Complicated urinary tract infections and pyelonephritis<br />10 mg/kg body weight twice daily to 20 mg/kg body weight twice daily with a maximum of 750 mg per dose.<br />10 to 21 days<br />Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate. Drug administration should begin as soon as possible after suspected or confirmed exposure.<br />10 mg/kg body weight twice daily to 15 mg/kg body weight twice daily with a maximum of 500 mg per dose.<br />60 days from the confirmation of Bacillus anthracis exposure<br />Other severe infections<br />20 mg/kg body weight twice daily with a maximum of 750 mg per dose.<br />According to the type of infections</p><p>Elderly patients should receive a dose selected according to the severity of the infection and the patient&#39;s creatinine clearance.<br />Patients with renal and hepatic impairment<br />Recommended starting and maintenance doses for patients with impaired renal function:<br />Creatinine Clearance<br />[mL/min/1.73 m2]<br />Serum Creatinine<br />[&mu;mol/L]<br />Oral Dose<br />[mg]<br />&gt; 60<br />&lt; 124<br />See Usual Dosage.<br />30-60<br />124 to 168<br />250-500 mg every 12 h<br />&lt; 30<br />&gt; 169<br />250-500 mg every 24 h<br />Patients on haemodialysis<br />&gt; 169<br />250-500 mg every 24 h (after dialysis)<br />Patients on peritoneal dialysis<br />&gt; 169<br />250-500 mg every 24 h<br />In patients with impaired liver function no dose adjustment is required.<br />Dosing in children with impaired renal and/or hepatic function has not been studied.<br />Method of administration<br />Tablets are to be swallowed unchewed with fluid. They can be taken independent of mealtimes. If taken on an empty stomach, the active substance is absorbed more rapidly. Ciprofloxacin tablets should not be taken with dairy products (e.g. milk, yoghurt) or mineral-fortified fruit-juice (e.g. calcium-fortified orange juice) (see section 4.5).<br />In severe cases or if the patient is unable to take tablets (e.g. patients on enteral nutrition), it is recommended to commence therapy with intravenous ciprofloxacin until a switch to oral administration is possible.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3 Contraindications
• Hypersensitivity to the active substance, to other quinolones or to any of the excipients listed in section 6.1.
• Concomitant administration of ciprofloxacin and tizanidine (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Severe infections and mixed infections with Gram-positive and anaerobic pathogens<br />Ciprofloxacin monotherapy is not suited for treatment of severe infections and infections that might be due to Gram-positive or anaerobic pathogens. In such infections ciprofloxacin must be co-administered with other appropriate antibacterial agents.<br />Streptococcal Infections (including Streptococcus pneumoniae)<br />Ciprofloxacin is not recommended for the treatment of streptococcal infections due to inadequate efficacy.<br />Genital tract infections<br />Gonococcal uretritis, cervicitis, epididymo-orchitis and pelvic inflammatory diseases may be caused by fluoroquinolone-resistant Neisseria gonorrhoeae isolates.<br />Therefore, ciprofloxacin should be administered for the treatment of gonococcal uretritis or cervicitis only if ciprofloxacin-resistant Neisseria gonorrhoeae can be excluded.<br />For epididymo-orchitis and pelvic inflammatory diseases, empirical ciprofloxacin should only be considered in combination with another appropriate antibacterial agent (e.g. a cephalosporin) unless ciprofloxacin-resistant Neisseria gonorrhoeae can be excluded. If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered.<br />Urinary tract infections<br />Resistance to fluoroquinolones of Escherichia coli &ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in Escherichia coli to fluoroquinolones.<br />The single dose of ciprofloxacin that may be used in uncomplicated cystitis in pre-menopausal women is expected to be associated with lower efficacy than the longer treatment duration. This is all the more to be taken into account as regards the increasing resistance level of Escherichia coli to quinolones.</p><p>Intra-abdominal infections<br />There are limited data on the efficacy of ciprofloxacin in the treatment of post-surgical intra-abdominal infections.<br />Travellers&#39; diarrhoea<br />The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.<br />Infections of the bones and joints<br />Ciprofloxacin should be used in combination with other antimicrobial agents depending on the results of the microbiological documentation.<br />Inhalational anthrax<br />Use in humans is based on in-vitro susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.<br />Paediatric population<br />The use of ciprofloxacin in children and adolescents should follow available official guidance. Ciprofloxacin treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents.<br />Ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature animals. Safety data from a randomised double-blind study on ciprofloxacin use in children (ciprofloxacin: n=335, mean age = 6.3 years; comparators: n=349, mean age = 6.2 years; age range = 1 to 17 years) revealed an incidence of suspected drug-related arthropathy (discerned from joint-related clinical signs and symptoms) by Day +42 of 7.2% and 4.6%. Respectively, an incidence of drug-related arthropathy by 1-year follow-up was 9.0% and 5.7%. The increase of suspected drug-related arthropathy cases over time was not statistically significant between groups. Treatment should be initiated only after a careful benefit/risk evaluation, due to possible adverse events related to joints and/or surrounding tissue (see section 4.8).<br />Broncho-pulmonary infections in cystic fibrosis<br />Clinical trials have included children and adolescents aged 5-17 years. More limited experience is available in treating children between 1 and 5 years of age.<br />Complicated urinary tract infections and pyelonephritis</p><p>Ciprofloxacin treatment of urinary tract infections should be considered when other treatments cannot be used, and should be based on the results of the microbiological documentation.<br />Clinical trials have included children and adolescents aged 1-17 years.<br />Other specific severe infections<br />Other severe infections in accordance with official guidance, or after careful benefit-risk evaluation when other treatments cannot be used, or after failure to conventional therapy and when the microbiological documentation can justify a ciprofloxacin use.<br />The use of ciprofloxacin for specific severe infections other than those mentioned above has not been evaluated in clinical trials and the clinical experience is limited. Consequently, caution is advised when treating patients with these infections.<br />Hypersensitivity<br />Hypersensitivity and allergic reactions, including anaphylaxis and anaphylactoid reactions, may occur following a single dose (see section 4.8) and may be life-threatening. If such reaction occurs, ciprofloxacin should be discontinued and an adequate medical treatment is required.<br />Musculoskeletal System<br />Ciprofloxacin should generally not be used in patients with a history of tendon disease/disorder related to quinolone treatment. Nevertheless, in very rare instances, after microbiological documentation of the causative organism and evaluation of the risk/benefit balance, ciprofloxacin may be prescribed to these patients for the treatment of certain severe infections, particularly in the event of failure of the standard therapy or bacterial resistance, where the microbiological data may justify the use of ciprofloxacin.<br />Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur with ciprofloxacin, even within the first 48 hours of treatment. Inflammation and ruptures of tendon may occur even up to several months after discontinuation of ciprofloxacin therapy. The risk of tendinopathy may be increased in elderly patients or in patients concomitantly treated with corticosteroids (see section 4.8).<br />At any sign of tendinitis (e.g. painful swelling, inflammation), ciprofloxacin treatment should be discontinued. Care should be taken to keep the affected limb at rest.<br />Ciprofloxacin should be used with caution in patients with myasthenia gravis, because symptoms can be exacerbated (see section 4.8).</p><p>Vision disorders<br />If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately.<br />Photosensitivity<br />Ciprofloxacin has been shown to cause photosensitivity reactions. Patients taking ciprofloxacin should be advised to avoid direct exposure to either extensive sunlight or UV irradiation during treatment (see section 4.8).<br />Central Nervous System<br />Ciprofloxacin like other quinolones are known to trigger seizures or lower the seizure threshold. Cases of status epilepticus have been reported. Ciprofloxacin should be used with caution in patients with CNS disorders which may be predisposed to seizure. If seizures occur ciprofloxacin should be discontinued (see section 4.8). Psychiatric reactions may occur even after first administration of ciprofloxacin. In rare cases, depression or psychosis can progress to suicidal ideations/thoughts culminating in attempted suicide or completed suicide. In the occurrence of such cases, ciprofloxacin should be discontinued.<br />Cases of polyneuropathy (based on neurological symptoms such as pain, burning, sensory disturbances or muscle weakness, alone or in combination) have been reported in patients receiving ciprofloxacin. Ciprofloxacin should be discontinued in patients experiencing symptoms of neuropathy, including pain, burning, tingling, numbness, and/or weakness in order to prevent the development of an irreversible condition (see section 4.8).<br />Cardiac disorders<br />Caution should be taken when using fluoroquinolones, including ciprofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:<br />&bull; congenital long QT syndrome<br />&bull; concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics)<br />&bull; uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia)<br />&bull; cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)<br />Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including ciprofloxacin, in these populations.</p><p>(See section 4.2 Elderly patients, section 4.5, section 4.8, section 4.9).<br />Hypoglycemia<br />As with other quinolones, hypoglycemia has been reported most often in diabetic patients, predominantly in the elderly population. In all diabetic patients, careful monitoring of blood glucose is recommended (see section 4.8).<br />Gastrointestinal System<br />The occurrence of severe and persistent diarrhoea during or after treatment (including several weeks after treatment) may indicate an antibiotic-associated colitis (life-threatening with possible fatal outcome), requiring immediate treatment (see section 4.8). In such cases, ciprofloxacin should immediately be discontinued, and an appropriate therapy initiated. Anti-peristaltic drugs are contraindicated in this situation.<br />Renal and urinary system<br />Crystalluria related to the use of ciprofloxacin has been reported (see section 4.8). Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided.<br />Impaired renal function<br />Since ciprofloxacin is largely excreted unchanged via renal pathway dose adjustment is needed in patients with impaired renal function as described in section 4.2 to avoid an increase in adverse drug reactions due to accumulation of ciprofloxacin.<br />Hepatobiliary system<br />Cases of hepatic necrosis and life-threatening hepatic failure have been reported with ciprofloxacin (see section 4.8). In the event of any signs and symptoms of hepatic disease (such as anorexia, jaundice, dark urine, pruritus, or tender abdomen), treatment should be discontinued.<br />Glucose-6-phosphate dehydrogenase deficiency<br />Haemolytic reactions have been reported with ciprofloxacin in patients with glucose-6-phosphate dehydrogenase deficiency. Ciprofloxacin should be avoided in these patients unless the potential benefit is considered to outweigh the possible risk. In this case, potential occurrence of haemolysis should be monitored.<br />Resistance<br />During or following a course of treatment with ciprofloxacin bacteria that demonstrate resistance to ciprofloxacin may be isolated, with or without a clinically apparent superinfection. There may&nbsp;be a particular risk of selecting for ciprofloxacin-resistant bacteria during extended durations of treatment and when treating nosocomial infections and/or infections caused by Staphylococcus and Pseudomonas species.<br />Cytochrome P450<br />Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e.g. theophylline, clozapine, olanzapine, ropinirole, tizanidine, duloxetine, agomelatine). Therefore, patients taking these substances concomitantly with ciprofloxacin should be monitored closely for clinical signs of overdose, and determination of serum concentrations (e.g. of theophylline) may be necessary (see section 4.5). Co-administration of ciprofloxacin and tizanidine is contra-indicated.<br />Methotrexate<br />The concomitant use of ciprofloxacin with methotrexate is not recommended (see section 4.5).<br />Interaction with tests<br />The in-vitro activity of ciprofloxacin against Mycobacterium tuberculosis might give false negative bacteriological test results in specimens from patients currently taking ciprofloxacin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects of other products on ciprofloxacin:<br />Drugs known to prolong QT interval<br />Ciprofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics) (see section 4.4).<br />Chelation Complex Formation<br />The simultaneous administration of ciprofloxacin (oral) and multivalent cation-containing drugs and mineral supplements (e.g. calcium, magnesium, aluminium, iron), polymeric phosphate binders (e.g. sevelamer or lanthanum carbonate), sucralfate or antacids, and highly buffered drugs (e.g. didanosine tablets) containing magnesium, aluminium, or calcium reduces the absorption of ciprofloxacin. Consequently, ciprofloxacin should be administered either 1-2 hours before or at least 4 hours after these preparations. The restriction does not apply to antacids belonging to the class of H2 receptor blockers.</p><p>Food and Dairy Products<br />Dietary calcium as part of a meal does not significantly affect absorption. However, the concurrent administration of dairy products or mineral-fortified drinks alone (e.g. milk, yoghurt, calcium-fortified orange juice) with ciprofloxacin should be avoided because absorption of ciprofloxacin may be reduced.<br />Probenecid<br />Probenecid interferes with renal secretion of ciprofloxacin. Co-administration of probenecid and ciprofloxacin increases ciprofloxacin serum concentrations.<br />Metoclopramide<br />Metoclopramide accelerates the absorption of ciprofloxacin (oral) resulting in a shorter time to reach maximum plasma concentrations. No effect was seen on the bioavailability of ciprofloxacin.<br />Omeprazole<br />Concomitant administration of ciprofloxacin and omeprazole containing medicinal products results in a slight reduction of Cmax and AUC of ciprofloxacin.<br />Effects of ciprofloxacin on other medicinal products:<br />Tizanidine<br />Tizanidine must not be administered together with ciprofloxacin (see section 4.3). In a clinical study with healthy subjects, there was an increase in serum tizanidine concentration (Cmax increase: 7-fold, range: 4 to 21-fold; AUC increase: 10-fold, range: 6 to 24-fold) when given concomitantly with ciprofloxacin. Increased serum tizanidine concentration is associated with a potentiated hypotensive and sedative effect.<br />Methotrexate<br />Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate and increased risk of methotrexate-associated toxic reactions. The concomitant use is not recommended (see section 4.4).<br />Theophylline<br />Concurrent administration of ciprofloxacin and theophylline can cause an undesirable increase in serum theophylline concentration. This can lead to theophylline-induced side effects that may rarely be life threatening or fatal. During the combination, serum theophylline concentrations should be checked and the theophylline dose reduced as necessary (see section 4.4).</p><p>Other xanthine derivatives<br />On concurrent administration of ciprofloxacin and caffeine or pentoxifylline (oxpentifylline), raised serum concentrations of these xanthine derivatives were reported.<br />Phenytoin<br />Simultaneous administration of ciprofloxacin and phenytoin may result in increased or reduced serum levels of phenytoin such that monitoring of drug levels is recommended.<br />Cyclosporin<br />A transient rise in the concentration of serum creatinine was observed when ciprofloxacin and cyclosporin containing medicinal products were administered simultaneously. Therefore, it is frequently (twice a week) necessary to control the serum creatinine concentrations in these patients.<br />Vitamin K antagonists<br />Simultaneous administration of ciprofloxacin with a vitamin K antagonist may augment its anti-coagulant effects. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of ciprofloxacin to the increase in INR (international normalised ratio) is difficult to assess. The INR should be monitored frequently during and shortly after co-administration of ciprofloxacin with a vitamin K antagonist (e.g., warfarin, acenocoumarol, phenprocoumon, or fluindione).<br />Duloxetine<br />In clinical studies, it was demonstrated that concomitant use of duloxetine with strong inhibitors of the CYP450 1A2 isozyme such as fluvoxamine, may result in an increase of AUC and Cmax of duloxetine. Although no clinical data are available on a possible interaction with ciprofloxacin, similar effects can be expected upon concomitant administration (see section 4.4).<br />Ropinirole<br />It was shown in a clinical study that concomitant use of ropinirole with ciprofloxacin, a moderate inhibitor of the CYP450 1A2 isozyme, results in an increase of Cmax and AUC of ropinirole by 60% and 84%, respectively. Monitoring of ropinirole-related side effects and dose adjustment as appropriate is recommended during and shortly after co-administration with ciprofloxacin (see section 4.4).</p><p>Lidocaine<br />It was demonstrated in healthy subjects that concomitant use of lidocaine containing medicinal products with ciprofloxacin, a moderate inhibitor of CYP450 1A2 isozyme, reduces clearance of intravenous lidocaine by 22%. Although lidocaine treatment was well tolerated, a possible interaction with ciprofloxacin associated with side effects may occur upon concomitant administration.<br />Clozapine<br />Following concomitant administration of 250 mg ciprofloxacin with clozapine for 7 days, serum concentrations of clozapine and N-desmethylclozapine were increased by 29% and 31%, respectively. Clinical surveillance and appropriate adjustment of clozapine dosage during and shortly after co-administration with ciprofloxacin are advised (see section 4.4).<br />Sildenafil<br />Cmax and AUC of sildenafil were increased approximately twofold in healthy subjects after an oral dose of 50 mg given concomitantly with 500 mg ciprofloxacin. Therefore, caution should be used prescribing ciprofloxacin concomitantly with sildenafil taking into consideration the risks and the benefits.<br />Agomelatine<br />In clinical studies, it was demonstrated that fluvoxamine, as a strong inhibitor of the CYP450 1A2 isoenzyme, markedly inhibits the metabolism of agomelatine resulting in a 60-fold increase of agomelatine exposure. Although no clinical data are available for a possible interaction with ciprofloxacin, a moderate inhibitor of CYP450 1A2, similar effects can be expected upon concomitant administration (see &#39;Cytochrome P450&#39; in section 4.4).<br />Zolpidem<br />Co-administration of ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The data that are available on administration of ciprofloxacin to pregnant women indicates no malformative or feto/neonatal toxicity of ciprofloxacin. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. In juvenile and prenatal animals exposed to quinolones, effects on immature cartilage have been observed, thus, it cannot be&nbsp;excluded that the drug could cause damage to articular cartilage in the human immature organism / foetus (see section 5.3).<br />As a precautionary measure, it is preferable to avoid the use of ciprofloxacin during pregnancy.<br />Breast-feeding<br />Ciprofloxacin is excreted in breast milk. Due to the potential risk of articular damage, ciprofloxacin should not be used during breast-feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to its neurological effects, ciprofloxacin may affect reaction time. Thus, the ability to drive or to operate machinery may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse drug reactions (ADRs) are nausea and diarrhoea.<br />ADRs derived from clinical studies and post-marketing surveillance with Neocipro (oral, intravenous, and sequential therapy) sorted by categories of frequency are listed below. The frequency analysis takes into account data from both oral and intravenous administration of ciprofloxacin.</p><p>System Organ Class<br />Common<br />&ge; 1/100 to &lt; 1/10<br />Uncommon<br />&ge; 1/1,000 to &lt; 1/100<br />Rare<br />&ge; 1/10,000 to &lt; 1/1,000<br />Very Rare<br />&lt; 1/10,000<br />Frequency not known<br />(cannot be estimated from the available data)<br />Infections and Infestations<br />Mycotic super-infections<br />Blood and Lymphatic System Disorders<br />Eosinophilia<br />Leukopenia<br />Anaemia<br />Neutropenia<br />Leukocytosis<br />Thrombocytopenia<br />Thrombocytaemia<br />Haemolytic anaemia<br />Agranulocytosis<br />Pancytopenia (life-threatening)<br />Bone marrow depression (life-threatening)</p><p>Immune System Disorders<br />Allergic reaction<br />Allergic oedema / angiooedema<br />Anaphylactic reaction<br />Anaphylactic shock (life-threatening) (see section 4.4)<br />Serum sickness-like reaction<br />Metabolism and Nutrition Disorders<br />Decreased appetite<br />Hyperglycaemia<br />Hypoglycaemia (see section 4.4)<br />Psychiatric Disorders<br />Psychomotor hyperactivity / agitation<br />Confusion and disorientation<br />Anxiety reaction<br />Abnormal dreams<br />Depression (potentially culminating in suicidal ideations/thoughts or suicide attempts and completed suicide) (see section 4.4)<br />Hallucinations<br />Psychotic reactions (potentially culminating in suicidal ideations/ thoughts or suicide attempts and completed suicide) (see section 4.4)<br />Mania, incl. hypomania<br />Nervous System Disorders<br />Headache<br />Dizziness<br />Sleep disorders<br />Taste disorders<br />Par- and Dysaesthesia<br />Hypoaesthesia<br />Tremor<br />Seizures (including status epilepticus see section 4.4)<br />Vertigo<br />Migraine<br />Disturbed coordination<br />Gait disturbance<br />Olfactory nerve disorders<br />Intracranial hypertension and pseudotumor cerebri)<br />Peripheral neuropathy and polyneuropathy (see section 4.4)</p><p>Eye Disorders<br />Visual disturbances (e.g. diplopia)<br />Visual colour distortions<br />Ear and Labyrinth Disorders<br />Tinnitus<br />Hearing loss / Hearing impaired<br />Cardiac Disorders<br />Tachycardia<br />Ventricular arrhythmia and torsades de pointes (reported predominantly in patients with risk factors for QT prolongation), ECG QT prolonged (see sections 4.4 and 4.9)<br />Vascular Disorders<br />Vasodilatation<br />Hypotension<br />Syncope<br />Vasculitis<br />Respiratory, Thoracic and Mediastinal Disorders<br />Dyspnoea (including asthmatic condition)<br />Gastrointestinal Disorders<br />Nausea<br />Diarrhoea<br />Vomiting<br />Gastrointestinal and abdominal pains<br />Dyspepsia<br />Flatulence<br />Antibiotic associated colitis (very rarely with possible fatal outcome) (see section 4.4)<br />Pancreatitis<br />Hepatobiliary Disorders<br />Increase in transaminases<br />Increased bilirubin<br />Hepatic impairment<br />Cholestatic icterus<br />Hepatitis<br />Liver necrosis (very rarely progressing to life-threatening hepatic failure) (see section 4.4)</p><p>Skin and Subcutaneous Tissue Disorders<br />Rash<br />Pruritus<br />Urticaria<br />Photosensitivity reactions (see section 4.4)<br />Petechiae<br />Erythema multiforme<br />Erythema nodosum<br />Stevens-Johnson syndrome (potentially life-threatening)<br />Toxic epidermal necrolysis (potentially life-threatening)<br />Acute Generalised Exanthematous Pustulosis (AGEP)<br />Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)<br />Musculo-skeletal and Connective Tissue Disorders<br />Musculo-skeletal pain (e.g. extremity pain, back pain, chest pain)<br />Arthralgia<br />Myalgia<br />Arthritis<br />Increased muscle tone and cramping<br />Muscular weakness<br />Tendinitis<br />Tendon rupture (predominantly Achilles tendon) (see section 4.4)<br />Exacerbation of symptoms of myasthenia gravis (see section 4.4)<br />Renal and Urinary Disorders<br />Renal impairment<br />Renal failure<br />Haematuria<br />Crystalluria (see section 4.4)<br />Tubulointerstitial nephritis<br />General Disorders and Administration Site Conditions<br />Asthenia<br />Fever<br />Oedema<br />Sweating (hyperhidrosis)</p><p>Investigations<br />Increase in blood alkaline phosphatase<br />Increased amylase<br />International normalised ratio increased (in patients treated with Vitamin K antagonists)<br />Paediatric population<br />The incidence of arthropathy (arthralgia, arthritis), mentioned above, is referring to data collected in studies with adults. In children, arthropathy is reported to occur commonly (see section 4.4).<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via.<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.<br />Reporting to National regulatory authority:<br />To report any side effects:<br />Saudi Arabia<br />The National Pharmacovigilance and Drug Safety Centre (NPC):<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Ext 2317-2356-2340<br />Reporting hotline: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.9 Overdose<br />An overdose of 12 g has been reported to lead to mild symptoms of toxicity. An acute overdose of 16 g has been reported to cause acute renal failure.<br />Symptoms in overdose consist of dizziness, tremor, headache, tiredness, seizures, hallucinations, confusion, abdominal discomfort, renal and hepatic impairment as well as crystalluria and haematuria. Reversible renal toxicity has been reported.<br />Apart from routine emergency measures, e.g. ventricular emptying followed by medical carbon, it is recommended to monitor renal function, including urinary pH and acidify, if required, to prevent</p><p>crystalluria. Patients should be kept well hydrated. Calcium or magnesium containing antacids may theoretically reduce the absorption of ciprofloxacin in overdoses<br />Only a small quantity of ciprofloxacin (&lt;10%) is eliminated by haemodialysis or peritoneal dialysis.<br />In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1 Pharmacodynamic properties<br />Pharmacotherapeutic group: Fluoroquinolones, ATC code: J01MA02<br />Mechanism of action:<br />As a fluoroquinolone antibacterial agent, the bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.<br />Pharmacokinetic/pharmacodynamic relationship relationship<br />Efficacy mainly depends on the relation between the maximum concentration in serum (Cmax) and the minimum inhibitory concentration (MIC) of ciprofloxacin for a bacterial pathogen and the relation between the area under the curve (AUC) and the MIC.<br />Mechanism of resistance<br />In-vitro resistance to ciprofloxacin can be acquired through a stepwise process by target site mutations in both DNA gyrase and topoisomerase IV. The degree of cross-resistance between ciprofloxacin and other fluoroquinolones that results is variable. Single mutations may not result in clinical resistance, but multiple mutations generally result in clinical resistance to many or all active substances within the class.<br />Impermeability and/or active substance efflux pump mechanisms of resistance may have a variable effect on susceptibility to fluoroquinolones, which depends on the physiochemical properties of the various active substances within the class and the affinity of transport systems for each active substance. All in-vitro mechanisms of resistance are commonly observed in clinical isolates. Resistance mechanisms that inactivate other antibiotics such as permeation barriers (common in Pseudomonas aeruginosa) and efflux mechanisms may affect susceptibility to ciprofloxacin.<br />Plasmid-mediated resistance encoded by qnr-genes has been reported.</p><p>Spectrum of antibacterial activity<br />Breakpoints separate susceptible strains from strains with intermediate susceptibility and the latter from resistant strains:<br />EUCAST Recommendations<br />Microorganisms<br />Susceptible<br />Resistant<br />Enterobacteriaceae<br />S &le; 0.5 mg/L<br />R &gt; 1 mg/L<br />Pseudomonas spp.<br />S &le; 0.5 mg/L<br />R &gt; 1 mg/L<br />Acinetobacter spp.<br />S &le; 1 mg/L<br />R &gt; 1 mg/L<br />Staphylococcus spp.1<br />S &le; 1 mg/L<br />R &gt; 1 mg/L<br />Haemophilus influenzae and Moraxella catarrhalis<br />S &le; 0.5 mg/L<br />R &gt; 0.5 mg/L<br />Neisseria gonorrhoeae<br />S &le; 0.03 mg/L<br />R &gt; 0.06 mg/L<br />Neisseria meningitidis<br />S &le; 0.03 mg/L<br />R &gt; 0.06 mg/L<br />Non-species-related breakpoints*<br />S &le; 0.5 mg/L<br />R &gt; 1 mg/L</p><p>1 Staphylococcus spp. - breakpoints for ciprofloxacin relate to high dose therapy.<br />* Non-species-related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and not for those species where susceptibility testing is not recommended.<br />The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.<br />Groupings of relevant species according to ciprofloxacin susceptibility (for Streptococcus species see section 4.4).<br />COMMONLY SUSCEPTIBLE SPECIES<br />Aerobic Gram-positive micro-organisms<br />Bacillus anthracis (1)<br />Aerobic Gram-negative micro-organisms<br />Aeromonas spp.<br />Brucella spp.</p><p>Citrobacter koseri<br />Francisella tularensis<br />Haemophilus ducreyi<br />Haemophilus influenzae*<br />Legionella spp.<br />Moraxella catarrhalis*<br />Neisseria meningitidis<br />Pasteurella spp.<br />Salmonella spp.*<br />Shigella spp.*<br />Vibrio spp.<br />Yersinia pestis<br />Anaerobic micro-organisms<br />Mobiluncus<br />Other micro-organisms<br />Chlamydia trachomatis ($)<br />Chlamydia pneumoniae ($)<br />Mycoplasma hominis ($)<br />Mycoplasma pneumoniae ($)<br />SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM<br />Aerobic Gram-positive micro-organisms<br />Enterococcus faecalis ($)<br />Staphylococcus spp.* (2)<br />Aerobic Gram-negative micro-organisms<br />Acinetobacter baumannii+<br />Burkholderia cepacia+*<br />Campylobacter spp.+*<br />Citrobacter freundii*<br />Enterobacter aerogenes<br />Enterobacter cloacae*<br />Escherichia coli*<br />Klebsiella oxytoca<br />Klebsiella pneumoniae*<br />Morganella morganii*<br />Neisseria gonorrhoeae*<br />Proteus mirabilis*<br />Proteus vulgaris*<br />Providencia spp.<br />Pseudomonas aeruginosa*<br />Pseudomonas fluorescens<br />Serratia marcescens*</p><p>Anaerobic micro-organisms<br />Peptostreptococcus spp.<br />Propionibacterium acnes<br />INHERENTLY RESISTANT ORGANISMS<br />Aerobic Gram-positive micro-organisms<br />Actinomyces<br />Enteroccus faecium<br />Listeria monocytogenes<br />Aerobic Gram-negative micro-organisms<br />Stenotrophomonas maltophilia<br />Anaerobic micro-organisms<br />Excepted as listed above<br />Other micro-organisms<br />Mycoplasma genitalium<br />Ureaplasma urealitycum<br />* Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications<br />+ Resistance rate &ge; 50% in one or more EU countries<br />($): Natural intermediate susceptibility in the absence of acquired mechanism of resistance<br />(1): Studies have been conducted in experimental animal infections due to inhalations of Bacillus anthracis spores; these studies reveal that antibiotics starting early after exposition avoid the occurrence of the disease if the treatment is made up to the decrease of the number of spores in the organism under the infective dose. The recommended use in human subjects is based primarily on in-vitro susceptibility and on animal experimental data together with limited human data. Two-month treatment duration in adults with oral ciprofloxacin given at the following dose, 500 mg bid, is considered as effective to prevent anthrax infection in humans. The treating physician should refer to national and/or international consensus documents regarding treatment of anthrax.<br />(2): Methicillin-resistant S. aureus very commonly express co-resistance to fluoroquinolones. The rate of resistance to methicillin is around 20 to 50% among all staphylococcal species and is usually higher in nosocomial isolates.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Following oral administration of single doses of 250 mg, 500 mg, and 750 mg of ciprofloxacin tablets, ciprofloxacin is absorbed rapidly and extensively, mainly from the small intestine, reaching maximum serum concentrations 1-2 hours later.</p><p>Single doses of 100-750 mg produced dose-dependent maximum serum concentrations (Cmax) between 0.56 and 3.7 mg/L. Serum concentrations increase proportionately with doses up to 1000 mg.<br />The absolute bioavailability is approximately 70-80%.<br />A 500 mg oral dose given every 12 hours has been shown to produce an area under the serum concentration-time curve (AUC) equivalent to that produced by an intravenous infusion of 400 mg ciprofloxacin given over 60 minutes every 12 hours.<br />Distribution<br />Protein binding of ciprofloxacin is low (20-30%). Ciprofloxacin is present in plasma largely in a non-ionised form and has a large steady state distribution volume of 2-3 L/kg body weight. Ciprofloxacin reaches high concentrations in a variety of tissues such as lung (epithelial fluid, alveolar macrophages, biopsy tissue), sinuses, inflamed lesions (cantharides blister fluid), and the urogenital tract (urine, prostate, endometrium) where total concentrations exceeding those of plasma concentrations are reached.<br />Biotransformation<br />Low concentrations of four metabolites have been reported, which were identified as: desethyleneciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) and formylciprofloxacin (M 4). The metabolites display in-vitroantimicrobial activity but to a lower degree than the parent compound.<br />Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.<br />Elimination<br />Ciprofloxacin is largely excreted unchanged both renally and, to a smaller extent, faecally. The serum elimination half-life in subjects with normal renal function is approximately 4-7 hours.<br />Excretion of ciprofloxacin (% of dose)<br />Oral Administration<br />Urine<br />Faeces<br />Ciprofloxacin<br />44.7<br />25.0<br />Metabolites (M1-M4)<br />11.3<br />7.5<br />Renal clearance is between 180-300 mL/kg/h and the total body clearance is between 480-600 mL/kg/h. Ciprofloxacin undergoes both glomerular filtration and tubular secretion. Severely impaired renal function leads to increased half lives of ciprofloxacin of up to 12 h.</p><p>Non-renal clearance of ciprofloxacin is mainly due to active trans-intestinal secretion and metabolism. 1% of the dose is excreted via the biliary route. Ciprofloxacin is present in the bile in high concentrations.<br />Paediatric patients<br />The pharmacokinetic data in paediatric patients are limited.<br />In a study in children Cmax and AUC were not age-dependent (above one year of age). No notable increase in Cmax and AUC upon multiple dosing (10 mg/kg three times daily) was observed.<br />In 10 children with severe sepsis Cmax was 6.1 mg/L (range 4.6-8.3 mg/L) after a 1-hour intravenous infusion of 10 mg/kg in children aged less than 1 year compared to 7.2 mg/L (range 4.7-11.8 mg/L) for children between 1 and 5 years of age. The AUC values were 17.4 mg*h/L (range 11.8-32.0 mg*h/L) and 16.5 mg*h/L (range 11.0-23.8 mg*h/L) in the respective age groups.<br />These values are within the range reported for adults at therapeutic doses. Based on population pharmacokinetic analysis of paediatric patients with various infections, the predicted mean half-life in children is approx. 4-5 hours and the bioavailability of the oral suspension ranges from 50 to 80%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazards for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential, or toxicity to reproduction.<br />Like a number of other quinolones, ciprofloxacin is phototoxic in animals at clinically relevant exposure levels. Data on photomutagenicity/ photocarcinogenicity show a weak photomutagenic or phototumorigenic effect of ciprofloxacin in-vitroand in animal experiments. This effect was comparable to that of other gyrase inhibitors.<br />Articular tolerability<br />As reported for other gyrase inhibitors, ciprofloxacin causes damage to the large weight-bearing joints in immature animals. The extent of the cartilage damage varies according to age, species and dose; the damage can be reduced by taking the weight off the joints. Studies with mature animals (rat, dog) revealed no evidence of cartilage lesions. In a study in young beagle dogs, ciprofloxacin caused severe articular changes at therapeutic doses after two weeks of treatment, which were still observed after 5 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1 List of excipients<br />S.No.<br />Ingredient<br />Function<br />EXCIPIENTS<br />1.<br />Microcrystalline Cellulose BP<br />Diluent<br />2.<br />Maize Starch BP<br />Diluent<br />3.<br />Sodium Starch Glycolate (Type A) BP<br />Disintegrant<br />4.<br />Colloidal Anhydrous Silica BP<br />Glidant<br />5.<br />Magnesium Stearate BP<br />Lubricant<br />6.<br />Hypromellose BP<br />Coating polymer<br />7.<br />Macrogol 400 BP<br />Plasticizer<br />8.<br />Titanium Dioxide BP<br />Opacifier</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister Packing using Aluminium foil on one side and PVDC-coated PVC film on other side. Pack size: 10‟s</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7. Manufacturer:
Neopharma, Abu Dhabi, UAE
Plot No. A1 89-95,
Industrial City of Abu Dhabi (ICAD),
Mussafah, Abu Dhabi, UAE
8. Marketing Authorization Holder:
Neopharma, Abu Dhabi, UAE
Plot No. A1 89-95,
Industrial City of Abu Dhabi (ICAD),
Mussafah, Abu Dhabi, UAE
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>